31 Pa. D. & C.5th 449
Pennsylvania Court of Common P...2013Background
- Defendant moves for summary judgment to dismiss plaintiff’s first amended complaint.
- Plaintiffs sue a generic drug manufacturer for state tort failure-to-warn claims.
- Generic uses the warning label of the brand-name drug; plaintiffs assume warnings are inadequate.
- PLIVA v. Mensing governs preemption, arguing state law cannot require label changes that conflict with federal labeling.
- Court discusses Wyeth v. Levine and the FDA’s Different Manufactures Exception to assess whether generic labeling may differ from brand-labels.
- Court ultimately dismisses all failure-to-warn claims and sets a schedule for further proceedings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Preemption of failure-to-warn claims against generic by PLIVA | PLIVA’s Different Manufactures Exception allows stronger generic warnings. | PLIVA preempts state-law warnings that would differ from brand labeling. | PLIVA preempts a generic’s failure-to-warn claims. |
| Effect of Different Manufactures Exception on labeling differences | Exception permits labeling differences due to different manufacturers. | Exception does not authorize divergence in warnings for active ingredients. | Different Manufactures Exception does not permit differing safety warnings for active ingredients. |
| Whether active-ingredient warnings must match brand-name labeling | Warnings for active ingredients may be strengthened under state law. | Generic labels must match brand labels per PLIVA interpretation. | Active-ingredient warnings must be the same; differences not permitted. |
| Whether other non-failure-to-warn claims survive or limitations apply | Non-warn claims may proceed; limitations analysis pending. | Discovery incomplete; limitations issue unresolved. | Court will address non-warn claims and limitations later; primary claims dismissed. |
Key Cases Cited
- PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (U.S. 2011) (preemption of state failure-to-warn claims against generics; labeling must match brand-name)
- Wyeth v. Levine, 555 U.S. 555 (U.S. 2009) (FDA labeling changes and preemption under CBE regulation; brand labeling)
- Zeneca Inc. v. Shalala, 213 F.3d 161 (4th Cir. 2000) (FDA labeling guidance on differences due to manufacturer)